Iambic Therapeutics Inc.
Iambic Therapeutics Inc.
Your view on IAM
Overview
What the company does, where it operates, and who runs it.
About Iambic Therapeutics Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Thomas Miller
- Headquarters
- 5627 Oberlin Drive, Suite 120, San Diego, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Thomas Miller
- Headquarters
- 5627 Oberlin Drive, Suite 120, San Diego, CA, US
Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas.
The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Iambic Therapeutics Inc. from FRC's valuation model, read against the market price. IAM last traded at $14.76; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Iambic Therapeutics Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Iambic Therapeutics Inc.. Iambic Therapeutics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Iambic Therapeutics Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$32.50
average of analysts' targets
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 19, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Iambic Therapeutics Inc.. Iambic Therapeutics Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
More Biotechnology companies
Market cap
- AMPEAmpio Pharmaceuticals, Inc.OTC$307,285
- ANABAnaptysBio, Inc.NASDAQ$1.4B
- ANEBAnebulo Pharmaceuticals, Inc.OTC$96M
- ANIXAnixa Biosciences, Inc.NASDAQ$91M
- ANLAdlai Nortye Ltd. American Depositary SharesNASDAQ$563M
- ANNXAnnexon, Inc.NASDAQ$642M
- ANR.AXAnatara Lifesciences LtdASX
- ANROAlto Neuroscience, Inc.NYSE$1.2B
- ANTHAnthera Pharmaceuticals, Inc.OTC$2,618
- ANTIAntigenics, Inc.OTC
- ANTXAN2 Therapeutics, Inc.NASDAQ$173M
- ANVSAnnovis Bio, Inc.NYSE$40M
ETFs holding Iambic Therapeutics Inc.
% of the fund
- ARKGARK Genomic Revolution ETF$2.2B in assets1.37%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- VXFVanguard Extended Market ETF$30.2B in assets0.00%
- VTWOVanguard Russell 2000 ETF$16.6B in assets0.00%
- VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.00%
- VTWVVanguard Russell 2000 Value ETF$1.3B in assets0.00%
- VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
Largest holders first, then the funds most concentrated in IAM.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Iambic Therapeutics Inc., and how their positions are changing. At a $138.4M market value, institutional positions materially move Iambic Therapeutics Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Iambic Therapeutics Inc. executives and directors. Shares of Iambic Therapeutics Inc. have traded between $9.60 and $25.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Iambic Therapeutics Inc.. Iambic Therapeutics Inc. is a $138.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Iambic Therapeutics Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Iambic Therapeutics Inc.. Coverage tracks Iambic Therapeutics Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Iambic Therapeutics Inc.